Vaxcyte ( PCVX )

Vaxcyte completes common stock offering, raising $600.2 million

PCVX

Vaxcyte, Inc. entered into an underwriting agreement on January 29, 2026, for the issuance and sale of 11,000,000 shares of its common stock at a public price of $50.00 per share.
The underwriters, including BofA Securities, Inc., Jefferies LLC, Leerink Partners LLC, and Evercore Group L.L.C., were granted a 30-day option to purchase up to an additional 1,650,000 shares.
On January 30, 2026, the underwriters notified Vaxcyte of their intent to exercise this option in full.
The offering, including the full exercise of the option, resulted in approximately $600.2 million in net proceeds to Vaxcyte and closed on February 2, 2026.

3 days ago

8-K

Vaxcyte Announces Pricing of Public Offering

PCVX

Vaxcyte, Inc. priced an underwritten public offering of 11,000,000 shares of common stock at $50.00 per share.
The offering is expected to generate aggregate gross proceeds of $550 million for Vaxcyte.
The underwriters have been granted a 30-day option to purchase up to an additional 1,650,000 shares of common stock.
The offering is expected to close on February 2, 2026.

7 days ago

Vaxcyte Commences Public Offering of Common Stock and Pre-Funded Warrants

PCVX

Vaxcyte, Inc. has commenced an underwritten public offering of $500,000,000 of its common stock and pre-funded warrants.
The company intends to grant the underwriters a 30-day option to purchase up to an additional $75,000,000 of common stock.
The offering is subject to market and other conditions, with no assurance as to whether or when it may be completed, or its actual size or terms.
BofA Securities, Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities are acting as joint book-running managers for the offering.

7 days ago

Vaxcyte Provides Updates on VAX-31 Adult and Infant Clinical Programs

PCVX

Product Launch

New Projects/Investments

Vaxcyte has dosed the first participants in the Phase 3 OPUS-2 study for its VAX-31 adult indication and plans to initiate the Phase 3 OPUS-3 study in the first quarter of 2026.
The company anticipates topline data from the OPUS-1 Phase 3 trial in the fourth quarter of 2026, and from OPUS-2 and OPUS-3 in the first half of 2027, supporting a planned Biologics License Application (BLA) submission.
For the VAX-31 infant indication, enrollment in the Phase 2 dose-finding study is complete, with topline data expected by the end of the first half of 2027.
Vaxcyte plans to begin building a custom fill-finish line in North Carolina in the first quarter of 2026, as part of a long-term commitment of up to $1 billion in U.S. manufacturing.

Jan 22, 2026, 10:00 PM

Vaxcyte Updates on FDA Interactions, Clinical Programs, and Financial Position

PCVX

New Projects/Investments

Guidance Update

Product Launch

Vaxcyte is engaging with the FDA on its pneumococcal conjugate vaccine programs, noting that a recently leaked memo regarding efficacy studies for vaccines is consistent with its existing development plans for both adult and infant populations.
The company plans to initiate a Phase 3 non-inferiority study for its 31-valent adult vaccine in December (2025), with results expected in 2026, aiming for a Biologics License Application (BLA) submission in 2027 and market entry in 2028.
For the infant population, Vaxcyte's 31-valent program Phase 2 study was modified to include higher doses, with data expected by the end of the first half of 2027. The infant market is estimated at $6 billion out of an $8 billion total market.
Vaxcyte reported a strong balance sheet with $2.7 billion at the end of September (2025), which is projected to fund operations until mid-2028, covering the adult VAX-31 program, infant programs, and manufacturing investments.

Dec 2, 2025, 6:20 PM

Vaxcyte Provides Update on FDA Interactions, Vaccine Development, and Financial Outlook

PCVX

New Projects/Investments

Guidance Update

Product Launch

Vaxcyte views a recent FDA memo regarding vaccine development requirements as consistent with their existing plans for adult pneumococcal conjugate vaccines, including a post-market study, and states it does not change their development plans for adult or infant populations.
The company expects to initiate a non-inferiority study for its phase 3 adult program for a 31-valent vaccine in December 2025, with readouts anticipated in 2026 and potential market entry in 2028.
For infants, the 31-valent program's phase 2 study is expected to provide data by the end of the first half of 2027, with ongoing efforts to optimize dosing for future phase 3 trials.
Vaxcyte reported a strong balance sheet with $2.7 billion in cash at the end of September 2025, which is projected to fund operations until mid-2028, covering the adult VAX-31 program through potential launch and advancing infant programs.

Dec 2, 2025, 6:20 PM

Vaxcyte Updates on Vaccine Development Programs and Financial Outlook

PCVX

New Projects/Investments

Guidance Update

Product Launch

Vaxcyte plans to initiate its Phase III non-inferiority study for the 31-valent adult vaccine in December 2025, with results expected in 2026, targeting a Biologics License Application (BLA) submission in 2027 and market entry in 2028.
The company's 31-valent infant program is currently enrolling patients in a modified Phase II study, with data anticipated by the end of the first half of 2027. Discussions suggest the possibility of an otitis media outcome study for infants, potentially avoiding a pneumococcal pneumonia outcome study requirement.
Vaxcyte maintains that a recently leaked FDA memo regarding vaccine development does not alter its existing development plans for either adult or infant populations, as their strategy aligns with the memo's content.
The company reported a strong balance sheet with $2.7 billion in cash at the end of September 2025, which is projected to fund operations through mid-2028, covering the adult Phase III program, infant program advancement, and manufacturing investments.

Dec 2, 2025, 6:20 PM

Vaxcyte Provides Update on VAX-31 Clinical Programs and Financial Position

PCVX

New Projects/Investments

Guidance Update

Vaxcyte is advancing its 31-valent pneumococcal conjugate vaccine (VAX-31), with the adult program set to initiate Phase 3 clinical development in December 2025.
The company anticipates disclosing PD4 (booster) data for the VAX-31 infant study by the end of the first half of 2027.
The pneumococcal conjugate vaccine market is projected to grow from its current $8 billion-$10 billion run rate to $12 billion-$15 billion in the next 5-10 years, driven significantly by the adult segment.
Vaxcyte reported a strong balance sheet with $2.7 billion as of September 30, 2025, expected to fund operations into the middle of 2028, and is on track with a $300 million-$350 million dedicated manufacturing facility with Lonza, due for completion in early 2026.

Nov 19, 2025, 2:30 PM

Vaxcyte to Initiate Adult VAX-31 Phase III Study in December 2025 and Provides Program Updates

PCVX

New Projects/Investments

Guidance Update

Vaxcyte plans to initiate its Phase III pivotal study for VAX-31 in adults in December 2025, following positive Phase II results that demonstrated superior coverage and immune responses compared to the 20-Valent vaccine.
The company expects to disclose Phase II PD4 (booster) data for its VAX-31 infant program by the end of the first half of 2027, with a potential earlier disclosure of PD3 data.
Vaxcyte has invested in a dedicated manufacturing facility with Lonza, costing $300 million-$350 million, which is on track for completion in early 2026 to support future product launches.
As of September 30, 2025, Vaxcyte reported $2.7 billion on its balance sheet, which is sufficient to fund operations and its Pneumococcal Conjugate Vaccine (PCV) programs into the middle of 2028.
Competitors such as Pfizer have pushed back the potential initiation of their 25-Valent program's Phase III to late 2026, while GSK's 30-plus valent program is in early Phase I development.

Nov 19, 2025, 2:30 PM

Earnings Transcripts

Quarterly earnings call transcripts for Vaxcyte.

Q4 2024

Feb 25, 2025

Q4 2023

Feb 27, 2024

Q4 2022

Feb 27, 2023

Q4 2021

Mar 1, 2022